RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 'Living Drug' trial offers hope for patients with incurable blood cancer
Disease control Not yet recruitingThis early-stage study is testing a new type of personalized treatment called CAR-T cell therapy for adults with multiple myeloma that has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab t…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Apr 04, 2026 00:35 UTC
-
New 'Living Drug' trial offers hope for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis early-stage study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy for people with relapsed or refractory multiple myeloma who have already tried at least three other treatments. Doctors will collect a patient's own immune cells, modify the…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Revived cancer drug tested in local clinics for hopeful patients
Disease control Not yet recruitingThis study is testing whether a drug called belantamab mafodotin, combined with a steroid, can be safely given every 6 weeks in local community clinics instead of every 3 weeks at large hospitals. It focuses on patients with multiple myeloma that has returned or stopped respondin…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Cristiana Costa Chase, DO • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for tough blood cancer: early trial tests experimental drug
Disease control Not yet recruitingThis early-stage study is testing a new drug called SG2918 in patients whose multiple myeloma has returned or stopped responding to other treatments. The main goal is to check if the drug is safe and what side effects it causes in about 40 participants. Researchers will also look…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC